BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant,  Gilead  Sciences  International  Limited,  submitted  on  4  May  2001  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for Viread, through the centralised procedure. After agreement by the CPMP on 23 January 2001, this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993, as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur:  Dr. Eric Abadie 
Co-Rapporteur:  Prof. De Andres-Trelles 
Scientific Advice 
The applicant did not seek a Scientific Advice from the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The  CPMP  during  its  24-26  April  2001  agreed  to  accelerate  the  evaluation  procedure  for  this 
medicinal product considering its potential high therapeutic interest. 
The procedure started on 22 May 2001. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 26 June 2001. 
The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 
6 July 2001. 
During the meeting on 24-26 July 2001, the CPMP agreed on a list of outstanding issues to be 
addressed in writing. The final list was sent to the applicant on 26 July 2001. 
The applicant submitted the responses to the list of outstanding issues on 24 August 2001. 
The Rapporteur and Co-rapporteur circulated the joint assessment report on the responses to the 
list of outstanding issues to all CPMP Members on 25 September 2001. 
During  the  CPMP  meeting  16-18  October  2001,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  under  exceptional  circumstances  to  Viread  on  18  October 
2001.  The  applicant  provided  an  undertaking  letter  of  the  specific  obligations  and  follow-up 
measures to be fulfilled post authorisation on 17 October 2001. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 5 February 2002. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
